Daniel Sánchez‐Cano

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.

Raquel Ríos-Fernández, JL Callejas Rubio, Daniel Sánchez‐Cano et al. · PubMed · 2010 · 80 citations

Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group

Daniel Sánchez‐Cano, Norberto Ortego‐Centeno, Vicent Fonollosa Plá et al. · Rheumatology International · 2018 · 72 citations

Pulmonary Pathology, Advanced Lung Disease, Systemic Scleroderma +8

Effect of Rituximab on Refractory Wegener Granulomatosis With Predominant Granulomatous Disease

Daniel Sánchez‐Cano, José Luís Callejas-Rubio, Norberto Ortego‐Centeno · JCR Journal of Clinical Rheumatology · 2008 · 35 citations

Prevalence of exercise pulmonary arterial hypertension in scleroderma.

José Luís Callejas-Rubio, Eduardo Moreno Escobar, Pilar Martín de la Fuente et al. · PubMed · 2008 · 35 citations